Highlights
-
• Patients with subjective cognitive impairment (SCI) reported worse quality of life (QOL) compared to patients with mild cognitive impairment and Alzheimer’s disease (AD).
-
• Caregiver-reported QOL for patients with SCI was better than caregivers of patients with AD and non-Alzheimer’s dementia.
-
• SCI significantly affects QOL, warranting further research and clinical consideration.
Introduction
The prevalence of dementia is on the rise, a reflection of both an aging population and improved public awareness of dementia symptoms and disease burden. Consequently, dementia is a common worry for older adults,Reference Roberts, McLaughlin and Connell1 and perceived cognitive impairment can be a significant source of anxiety for many people.Reference Stewart2,Reference Cutler and Brăgaru3 As awareness of dementia grows, a new group of patients has emerged: those with subjective cognitive impairment (SCI). These are patients who are concerned they have dementia but are neurologically normal, with a neuropsychological profile that is within normal limits once adjustments for age and demographic factors are accounted for.
Concerns around declining cognitive function have a deleterious effect on psychological well-being [4], and these concerns are pervasive among middle-aged and older adultsReference Corner and Bond.5 Dementia, particularly Alzheimer’s disease (AD), is an especially dreaded condition because it is considered to be irreversibleReference Daviglus, Bell and Berrettini.6 These concerns are well-documented in the literature as “anticipatory dementia” and “dementia worry.”Reference Cutler and Hodgson7,Reference Kessler, Bowen, Baer, Froelich and Wahl8
The prognosis of SCI is variable. Earlier work by our group showed that the likelihood of progression of SCI to measurable neurological decline is low, although a small proportion of people studied did go on to develop pathology.Reference Sutherland, Kirk, Karunanayake, O’Connell and Morgan9 SCI is of growing interest now because it may herald abnormal cognitive decline and may be a risk factor for dementia.Reference Stewart2,Reference Sutherland, Kirk, Karunanayake, O’Connell and Morgan9–Reference Mitchell, Kemp, Benito-León and Reuber12 Thus, some patients with SCI are at risk of disease progression, some will remain as the “worried well” and some patients’ SCI represents early pathology.
Methods
610 patients were seen at the Rural and Remote Memory Clinic (RRMC) between March 2004 and June 2019. These people were categorized into four diagnostic groups. 166 patients were neurologically and neuropsychologically normal and diagnosed with SCI, 98 were diagnosed with mild cognitive impairment (MCI), 228 were diagnosed with AD and 118 were diagnosed with non-Alzheimer’s dementia (non-AD).
The University of Saskatchewan’s RRMC is a centralized interdisciplinary clinic dedicated to assessing and caring for patients with memory concerns from rural Saskatchewan. Patients can be referred by primary care providers such as a family physician or nurse practitioner. At the initial visit, the patient sees a neurologist, physiotherapist and nurse and undergoes neuropsychological testing. A neuropsychology team assesses premorbid ability, attention, speeded mental processing, receptive and expressive language, visuospatial abilities, executive function and verbal and visual memory. The patient also undergoes a standard workup for causes of dementia including blood tests and neuroimaging. Other data collected at the initial visit include age, sex, years of formal education, Mini-Mental Status Exam (MMSE), Center for Epidemiologic Studies Depression Scale (CES-D), Functional Activities Questionnaire (FAQ), alcohol consumption, marital status, hours per week of work, past medical history, sleep concerns, possession of a driver’s license and family history of memory concerns. Assessments take one full day. At the end of the day, patients are given a diagnosis as agreed upon by the multidisciplinary team. More details about the RRMC can be found in previous publications.Reference Sutherland, Kirk, Karunanayake, O’Connell and Morgan9,Reference Wong, Kirk, Perlett, Karunanayake, Morgan and O’Connell13–Reference Morgan, Crossley and Kirk23
A diagnosis of SCI is given if patients meet the following criteria: no clinical evidence of neurologic disease; normal neuroimaging; and normal performance on neuropsychological testing relative to normative comparison standards that are adjusted for demographic
variables, which include age and for some tests, biological sex and level of formal education.
For this study, the main measure we assessed was the Quality of Life of the Patient Scale (QOLPT),Reference Logsdon, Gibbons, McCurry and Teri24 which patients complete upon their initial visit to the RRMC. The QOLPT scale is a brief assessment of patient quality of life (QOL) as determined through self-report and caregiver-report. Both the patient and their caregiver complete a version of the scale to evaluate the patient’s QOL. The QOLPT is comprised of 13 items, each scored between 1and 4, with overall scores ranging from 13 to 52. Higher scores indicate higher patient QOL. Self-reported and caregiver-reported patient QOLPT scores were compared across the four diagnostic groups: SCI, MCI, AD and non-AD.
Participants were eligible to participate in this study if they presented to the RRMC within the timeframe of data collection and completed the necessary testing. We avoided potential bias by analyzing data without patient identifiers. In addition, those involved in data analysis were not involved in seeing the patients in the clinic. Descriptive analyses were completed using frequencies, measures of central tendencies and variability. The QOLPT scores of different diagnostic groups were compared using the analysis of variance test. Statistical analyses were completed using SPSS version 27. Ethics approval was obtained from the University of Saskatchewan Biomedical Research Ethics Board.
Results
In total, 464 patients and 537 caregivers had complete data and were therefore included in the analysis. Within the population of patients, 148 were diagnosed with SCI, 77 were diagnosed with MCI, 167 were diagnosed with AD and 72 were diagnosed with non-AD dementia. In the caregiver group, 129 cared for patients with SCI, 89 cared for patients with MCI, 209 cared for patients with AD and 110 cared for patients with non-AD dementia. Table 1 summarizes the groupings for patients and caregivers.
Table 1. Total number of patients and caregivers by diagnostic grouping
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20250206125839063-0202:S0317167124003688:S0317167124003688_tab1.png?pub-status=live)
SCI = subjective cognitive impairment; MCI = mild cognitive impairment; AD = Alzheimer’s disease.
A summary of the demographic characteristics of the patients at the time of their initial clinic visit can be found in Table 2.
Table 2. Demographic characteristics of patients on clinic day
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20250206125839063-0202:S0317167124003688:S0317167124003688_tab2.png?pub-status=live)
SCI = subjective cognitive impairment; MCI = mild cognitive impairment; AD = Alzheimer’s disease.
Mean patient QOL scores as determined by self-report and caregiver-report on the QOLPT scale are summarized in Table 3.
Table 3. Quality of Life of the Patient Scale (QOLPT) scores (mean ± SD)
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20250206125839063-0202:S0317167124003688:S0317167124003688_tab3.png?pub-status=live)
SCI = subjective cognitive impairment; MCI = mild cognitive impairment; AD = Alzheimer’s disease.
Despite being neurologically and neuropsychologically normal, patients with SCI self-reported significantly lower QOLPT scores compared to patients with AD (mean 34.55 vs 35.96, p < 0.05). However, caregivers reported the opposite pattern, as SCI caregivers rated patient QOL higher than AD caregivers (mean 34.61 vs 31.72, p < 0.001).
Patients with SCI self-reported lower QOL than patients with MCI (mean 34.55 vs 36.97, p < 0.05). Caregivers of these two groups did not significantly differ in their ratings of patient QOL (mean 34.61 vs 34.52, p = 0.912).
Caregivers of patients with SCI reported higher patient QOL than caregivers of patients with non-AD dementia (mean 34.61 vs 31.17, p < 0.001). However, patients with SCI did not have significantly different QOL scores from those with non-AD dementia (mean 34.55 vs 34.81, p = 0.768).
Caregivers of patients with MCI also rated higher patient QOL than their AD counterparts (mean 34.52 vs 31.72, p < 0.001), but there were no differences between these two groups in the patient ratings (mean 36.97 vs 35.96, p = 0.215).
Patients with MCI self-reported higher QOL compared to patients with non-AD dementia (mean 36.97 vs 34.81, p < 0.05). Caregivers in these two groups responded similarly: caregivers of patients with MCI also reported higher patient QOL than caregivers of patients with non-AD (mean 34.52 vs 31.72, p < 0.001).
There were no statistically significant differences between the AD and non-AD groups for patients (mean 35.96 vs 34.81, p = 0.169) nor caregivers (mean 31.72 vs 31.17, p = 0.459). Table 4 summarizes these findings.
Table 4. Comparison of QOLPT scores between patient and caregiver reports for SCI, MCI AD and non-AD groups at initial assessment using ANOVA
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20250206125839063-0202:S0317167124003688:S0317167124003688_tab4.png?pub-status=live)
*= significant when p < 0.05. QOLPT = Quality of Life of the Patient Scale; SCI = subjective cognitive impairment; MCI = mild cognitive impairment; AD = Alzheimer’s disease.
The results of patient results for the MMSE, FAQ and CES-D are summarized in Table 5.
Table 5. MMSE, FAQ and CES-D scores by patient grouping
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20250206125839063-0202:S0317167124003688:S0317167124003688_tab5.png?pub-status=live)
MMSE = Mini-Mental Status Exam; FAQ = Functional Activities Questionnaire; CES-D = Center for Epidemiologic Studies Depression Scale; SCI = subjective cognitive impairment; MCI = mild cognitive impairment; AD = Alzheimer’s disease.
CES-D scores were significantly higher in patients with SCI compared to patients with MCI (mean 16.77 vs 13.61, p = 0.023). CES-D scores were also significantly higher in SCI patients than in AD patients (mean 16.77 vs 12.47, p < 0.001). There were no significant differences in CES-D scores between patients with SCI vs non-AD, MCI vs AD, MCI vs non-AD and AD vs non-AD.
Discussion
The goal of this study was to elucidate the QOL in patients with SCI living in rural and remote Saskatchewan. We assessed this by comparing self-reported and caregiver-reported measures of patient QOL and compared it to scores for patients diagnosed with MCI, AD and non-AD dementia.
Patients with SCI self-reported significantly worse QOL than patients diagnosed with MCI and AD, despite patients with SCI lacking clinically significant cognitive deficits. Interestingly, the opposite trend was found in caregivers. Caregiver-rated patient QOL was higher for patients with SCI compared to patients with AD and non-AD. We also found that patients with MCI self-reported better QOL than patients with non-AD and that caregivers of patients with MCI reported better patient QOL compared to their AD and non-AD counterparts.
It is possible that depressive symptoms contribute to the lower QOL scores seen in patients with SCI. This is in keeping with previous work done by our group, which characterized increased depressive symptomatology in this population,Reference Verity, Kirk, O’Connell, Karunanayake and Morgan16 and the relationship between depression, memory concerns and QOL is multifaceted. Depression can be an independent contributor to memory concerns, particularly given that our subset of patients with SCI tended to be younger; depression can also be an early symptom of dementia, and these two entities also have some behavioral overlap such as apathy. Furthermore, the psychological distress from heightened awareness of memory lapses could also contribute to these mood symptoms. Ultimately, these findings still underscore that patients with SCI have worse QOL, even if depression is a contributing factor, which is important to bear in mind when providing comprehensive care to these patients. Therefore, screening for and treating depression could be part of the interventions offered to patients with SCI.
SCI is a common and distressing experience for older adults. Despite not being diagnosed with a disease, our results demonstrate that SCI is an important condition for clinicians to be aware of because of its impact on QOL despite patients being perceived as clinically well. That SCI has a negative impact on QOL is consistent with other findings in the literature.Reference Stewart2–Reference Hill, McDermott and Mogle4,Reference Montejo, Montenegro, Fernandez and Maestu25,Reference Jenkins, Tree, Thornton and Tales26 Many mechanisms have been proposed for why this occurs. SCI can negatively affect patient QOL through patients worrying about their memory and forgetfulness.Reference Mol, van Boxtel, Willems and Jolles27 For some patients, SCI represents feelings of loss of control and meaning in life.Reference Sims, Whitfield, Ayotte, Gamaldo, Edwards and Allaire28,Reference Steinberg, Negash and Sammel29 The reduced ratings in QOL could reflect that patients with SCI experience increased affective symptoms.Reference Hill, Mogle and Wion30. SCI can also result in decreased engagement in activities31 and more functional problems.Reference Comijs, Deeg, Dik, Twisk and Jonker32,Reference Ogata, Hayashi, Sugiura and Hayakawa33 The societal and economic toll of SCI will only increase as the population ages.
Assessments for SCI can be difficult due to the variability and challenges in identifying itReference Hill, McDermott and Mogle.4 In one study, older adults ranked subjective memory impairment as more concerning than angina, asthma, hypertension or previous myocardial infarction, even though medical help-seeking through raising their concerns with their family physician was very low.Reference Begum, Morgan, Chiu, Tylee and Stewart34 This suggests that SCI may even be underreported. Many factors can impact help-seeking behaviors for patients with SCI such as personal concern about symptoms, perceived attitudes of their primary care providers and the availability of resources that can provide reassurance.Reference Begum, Morgan, Chiu, Tylee and Stewart34,Reference Begum, Whitley, Banerjee, Matthews, Stewart and Morgan35 Lack of interest by clinicians has also been identified as a contributor as to why SCI is underreported.Reference Stewart2 The patients in our study sought help by obtaining a referral to the RRMC, so it is possible that our sample does not capture the breadth of experience of patients living with SCI, especially in terms of their QOL.
Interventions for SCI have been a growing area of need, which our findings in this study support. Some work has been done around interventions such as “memory fitness” trainingReference Power, Kirwan and Palmer36,Reference Miller, Siddarth and Gaines37 and nutrition,Reference Richter, Herzog, Eyal and Cohen38 but the evidence for these interventions is not robust, and not much is known about their efficacy. One study showed that an intervention consisting of educational materials on cognitive aging and compensatory skills and behavior improved patients’ negative emotional reactions to their cognition compared to controls.Reference Hoogenhout, de Groot, Van der Elst and Jolles39
Overall, QOL in patients with SCI has been insufficiently studied to date and therefore represents an important gap in the field. In conjunction with our findings that patients with SCI self-report worse QOL than patients with MCI and AD, this demonstrates the need for future work on how patients with SCI can be supported to improve their QOL.
Acknowledgments
Thank you to the RRMC at the University of Saskatchewan for the support of this research.
Author contributions
All authors contributed in preparing and editing the final manuscript. GS wrote the manuscript under AK’s guidance. AK and GS developed the study design and AK oversaw data collection. CK performed the statistical analysis. DM participated in the conception of the RRMC clinical model and managed data entry. MEO and AK oversaw clinical assessments and performed the diagnosis. MEO administered and oversaw neuropsychological testing, depression testing and function testing.
Funding statement
AK has received an honorarium from Lilly for a speaking engagement and has participated in advisory boards for Lilly, Elsai, Roche and Paladin. The other authors have no conflicts to disclose. We did not receive funding for this project.
Competing interests
None to declare.